NCT06103838View on ClinicalTrials.gov

18F-Fluciclovine PET/CT in Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

December 6, 2026

Study Completion Date

December 6, 2031

Conditions
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
DRUG

18F-fluciclovine injection

370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.

PROCEDURE

18F-FDG PET/CT

All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH